Early Detection of Recurrent Ovarian Cancer in Patients with Low-Level Increases in Serum CA-125 Levels by 2-[F-18]Fluoro-2-Deoxy- <scp>d</scp> -Glucose-Positron Emission Tomography/Computed Tomography

Abstract

FDG-PET/CT has the ability to detect recurrent ovarian cancer and second primary tumors in patients with increased levels of serum CA-125. FDG-PET/CT affects the clinical management by localizing recurrent lesions and creating a specific treatment plan for each patient, especially patients who demonstrate a low-level increase in serum CA-125 levels.